Centogene N.V. (CNTGF)CNTGF

Upturn Advisory Summary

Analysis of Past Performance​

Type: Stock	Upturn Star Rating​	Today’s Advisory: PASS
Historic Profit: -51.32%	Upturn Advisory Performance 2	Avg. Invested days: 40
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -51.32%	Avg. Invested days: 40
Upturn Star Rating​	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 2

Key Highlights

Earnings Date

Valuation

Analyst Ratings

About Centogene N.V.

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.